Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort
Marie Hairing Enemark, Jonas Klejs Hemmingsen, Maja Dam Andersen, Trine Engelbrecht Hybel, Mads Emil Bjørn, Pär Lars Josefsson, Lars Møller Pedersen, Maja Bech Juul, Robert Schou Pedersen, Michael Thorsgaard, Ida Blok Sillesen, Trine Lindhardt Plesner, Stephen Jacques Hamilton-Dutoit, Paw Jensen, Charlotte Madsen, Maja Ludvigsen
{"title":"Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort","authors":"Marie Hairing Enemark, Jonas Klejs Hemmingsen, Maja Dam Andersen, Trine Engelbrecht Hybel, Mads Emil Bjørn, Pär Lars Josefsson, Lars Møller Pedersen, Maja Bech Juul, Robert Schou Pedersen, Michael Thorsgaard, Ida Blok Sillesen, Trine Lindhardt Plesner, Stephen Jacques Hamilton-Dutoit, Paw Jensen, Charlotte Madsen, Maja Ludvigsen","doi":"10.1038/s41408-024-01150-3","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"8 1","pages":""},"PeriodicalIF":12.9000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41408-024-01150-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
期刊介绍:
Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as:
Preclinical studies of new compounds, especially those that provide mechanistic insights
Clinical trials and observations
Reviews related to new drugs and current management of hematologic malignancies
Novel observations related to new mutations, molecular pathways, and tumor genomics
Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.